MX2017002878A - Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide. - Google Patents

Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide.

Info

Publication number
MX2017002878A
MX2017002878A MX2017002878A MX2017002878A MX2017002878A MX 2017002878 A MX2017002878 A MX 2017002878A MX 2017002878 A MX2017002878 A MX 2017002878A MX 2017002878 A MX2017002878 A MX 2017002878A MX 2017002878 A MX2017002878 A MX 2017002878A
Authority
MX
Mexico
Prior art keywords
corticosteroid
pi3k delta
dual pi3k
compositions
treatment
Prior art date
Application number
MX2017002878A
Other languages
English (en)
Inventor
Viswanadha Srikant
Kumar Venkata Satya Vakkalanka Swaroop
Original Assignee
Rhizen Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals Sa filed Critical Rhizen Pharmaceuticals Sa
Publication of MX2017002878A publication Critical patent/MX2017002878A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente descripción se refiere a un método para tratar enfermedades o afecciones autoinmunitarias, respiratorias y/o inflamatorias, p. ej., asma, EPOC, artritis reumatoide y fibrosis pulmonar idiopática (FPI). El método comprende administrar un inhibidor de PI3K delta y gamma doble y un corticosteroide. La presente invención también se refiere a composiciones farmacéuticas que contienen un inhibidor de PI3K delta y gamma doble y un corticosteroide.
MX2017002878A 2014-09-03 2015-09-03 Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide. MX2017002878A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4287CH2014 2014-09-03
PCT/IB2015/056720 WO2016035032A1 (en) 2014-09-03 2015-09-03 Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid

Publications (1)

Publication Number Publication Date
MX2017002878A true MX2017002878A (es) 2017-05-30

Family

ID=54249540

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017002878A MX2017002878A (es) 2014-09-03 2015-09-03 Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide.
MX2020011472A MX2020011472A (es) 2014-09-03 2017-03-03 Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011472A MX2020011472A (es) 2014-09-03 2017-03-03 Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide.

Country Status (25)

Country Link
US (2) US10786504B2 (es)
EP (2) EP3701950A1 (es)
JP (3) JP6559775B2 (es)
KR (1) KR20170044203A (es)
CN (2) CN113332439A (es)
AU (2) AU2015310545B2 (es)
BR (1) BR112017004163A2 (es)
CA (1) CA2958988A1 (es)
CL (1) CL2017000512A1 (es)
CY (1) CY1123075T1 (es)
DK (1) DK3188759T3 (es)
EA (2) EA038527B1 (es)
ES (1) ES2802202T3 (es)
HR (1) HRP20200968T1 (es)
HU (1) HUE049480T2 (es)
IL (2) IL250918B (es)
LT (1) LT3188759T (es)
MX (2) MX2017002878A (es)
PH (1) PH12017500378A1 (es)
PL (1) PL3188759T3 (es)
PT (1) PT3188759T (es)
RS (1) RS60450B1 (es)
SG (2) SG10202100596SA (es)
SI (1) SI3188759T1 (es)
WO (1) WO2016035032A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116492351B (zh) * 2023-03-13 2024-03-12 香港大学深圳医院 氯替泼诺在制备治疗早发性卵巢功能不全及卵巢响应匮乏药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018774A (en) 1976-02-13 1977-04-19 E. R. Squibb & Sons, Inc. Steroidal [16α,17-d]isoxazolidines
SE8106165L (sv) 1981-10-19 1983-04-20 Atlas Copco Ab Forfarande for bergbultning och bergbult
GB0415747D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
KR101897881B1 (ko) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US11058699B2 (en) 2008-07-01 2021-07-13 Wisconsin Alumni Research Foundation Method and compositions for inhibition of double stranded DNA viruses
CN102481282A (zh) * 2009-03-24 2012-05-30 新加坡国立大学 青蒿素衍生物用于治疗哮喘和慢性阻塞性肺病(copd)的用途
AU2010294598B2 (en) 2009-09-11 2016-09-01 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
AU2010316780B2 (en) 2009-11-05 2015-07-16 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
WO2011094598A2 (en) * 2010-01-28 2011-08-04 The Johns Hopkins University Compositions and methods for reversing corticosteroid resistance or treating respiratory infections
EP2533799B8 (en) * 2010-02-08 2019-12-25 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012123482A2 (en) 2011-03-15 2012-09-20 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
MY168757A (en) * 2011-05-04 2018-12-04 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
SE540189C2 (en) 2012-05-22 2018-04-24 Epiroc Canada Inc Rock bolt and method of installing the rock bolt and a protecting sleeve for it
KR20150079745A (ko) * 2012-11-08 2015-07-08 리젠 파마슈티컬스 소시에떼 아노님 Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
CN204282361U (zh) 2014-12-11 2015-04-22 湖南科技大学 一种带钢丝网的软土地基充气锚杆

Also Published As

Publication number Publication date
CY1123075T1 (el) 2021-10-29
LT3188759T (lt) 2020-07-10
JP2017525739A (ja) 2017-09-07
AU2021200051A1 (en) 2021-02-18
CN106714842B (zh) 2021-07-02
RS60450B1 (sr) 2020-07-31
AU2015310545A1 (en) 2017-03-16
EP3188759A1 (en) 2017-07-12
JP2019172708A (ja) 2019-10-10
KR20170044203A (ko) 2017-04-24
DK3188759T3 (da) 2020-06-29
CA2958988A1 (en) 2016-03-10
ES2802202T3 (es) 2021-01-15
HUE049480T2 (hu) 2020-09-28
JP6559775B2 (ja) 2019-08-14
US20170281630A1 (en) 2017-10-05
EA202092492A1 (ru) 2021-07-30
HRP20200968T1 (hr) 2020-10-16
IL280686A (en) 2021-03-25
AU2015310545B2 (en) 2020-10-22
EA038527B1 (ru) 2021-09-10
EA201790379A1 (ru) 2017-06-30
EP3701950A1 (en) 2020-09-02
MX2020011472A (es) 2020-12-07
IL250918B (en) 2021-02-28
SG11201701499YA (en) 2017-03-30
CN113332439A (zh) 2021-09-03
US20210030757A1 (en) 2021-02-04
US10786504B2 (en) 2020-09-29
PT3188759T (pt) 2020-07-02
PL3188759T3 (pl) 2020-11-02
JP2021191804A (ja) 2021-12-16
BR112017004163A2 (pt) 2017-12-05
CL2017000512A1 (es) 2017-11-03
EP3188759B1 (en) 2020-04-01
PH12017500378A1 (en) 2017-07-17
WO2016035032A1 (en) 2016-03-10
SI3188759T1 (sl) 2020-08-31
SG10202100596SA (en) 2021-02-25
CN106714842A (zh) 2017-05-24
IL250918A0 (en) 2017-04-30
NZ729419A (en) 2021-08-27

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL274134A (en) Methods of treating or preventing asthma by administering an IL-4R agonist
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EA201590721A1 (ru) Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX2018006195A (es) Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
MX2019005526A (es) Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa.
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
EA033163B1 (ru) Ингибиторы глутаминазы
GEP20186921B (en) Pyrazolopyridines and pyrazolopyrimidines
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
PH12017500927A1 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2017005281A (es) Etil n-boc piperidinil pirazolo piridonas como inhibidores de janus quinasa.
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
HK1247926A1 (zh) 四氫-n，n-二甲基-2，2-二苯基-3-呋喃甲胺鹽酸鹽的晶型，製備這樣晶型的方法，及其藥物組合物
WO2016168553A8 (en) Deuterated obeticholic acid
ZA201605492B (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MX2020011472A (es) Metodo de tratamiento y composiciones que comprenden un inhibidor de cinasa pi3k delta-gamma doble y un corticosteroide.
JOP20200104A1 (ar) مركبات مثبطة لـ btk
PH12016501808B1 (en) Chemical compounds

Legal Events

Date Code Title Description
FG Grant or registration